Peer-influenced content. Sources you trust. No registration required. This is HCN.

MD NewslineAZD4635 with Durvalumab or Oleclumab for Metastatic Castration-Resistant Prostate Cancer

Minimal Antitumor Efficacy of AZD4635 with Immunotherapy in Pre-Treated mCRPC Patients

In a recent phase 2 study published in Cancer Immunology, Immunotherapy, the combination of AZD4635 with either durvalumab or oleclumab was evaluated for its antitumor effects in patients with metastatic castration-resistant prostate cancer (mCRPC) who had undergone previous treatments. Although the regimen was found to be safe and well-tolerated, its efficacy in reducing tumor size was minimal, suggesting a limited role of adenosine 2A receptor antagonism in the current therapeutic landscape of mCRPC.

Key Points:

  • Patient Demographics and Treatment Background: The study enrolled 59 participants with a median age of 72 years, heavily pretreated for mCRPC. These participants were divided into two cohorts: 30 received AZD4635 with oleclumab, and 29 with durvalumab.
  • Treatment Duration and Response: The average treatment duration was slightly over three months. Only one patient in each cohort showed a confirmed response to the treatment, highlighting the limited efficacy of the regimen.
  • Stability and Progression: In the cohort treated with durvalumab, seven patients achieved stable disease for at least 35 days; however, a significant number experienced disease progression. Similarly, in the oleclumab cohort, eight patients maintained stable disease for the same duration.
  • PSA Response: A prostate-specific antigen (PSA) response was observed in a small subset of patients, with two in the durvalumab cohort and three in the oleclumab cohort showing reduced PSA levels.
  • Survival Outcomes: The median radiological progression-free survival was 2.3 months for durvalumab and 1.5 months for oleclumab recipients, with the median overall survival of 10.7 months reported only in the durvalumab group.
  • Safety and Adverse Events: Common adverse events included nausea and fatigue, with a small number of patients experiencing severe adverse events. The majority of deaths were attributed to the underlying disease rather than the treatment.

HCN Medical Memo
The phase 2 study assessing the efficacy of AZD4635 in combination with durvalumab or oleclumab for treating metastatic castration-resistant prostate cancer presents a crucial insight into the limited potential of adenosine 2A receptor antagonism in this advanced cancer stage and serves as a reminder of the challenging nature of mCRPC treatment and the critical need for innovative approaches that could provide more substantial benefits to patients.

More on Immunotherapy

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form